The startup is a clinical-stage biopharmaceutical company focused on developing cancer therapies that utilize receptor-targeting technology to selectively bind to overexpressed receptors on cancer cells. This approach aims to minimize toxicity risks associated with traditional cancer treatments, enhancing patient safety and treatment efficacy.

Agragene utilizes Precision-Guided Sterile Insect Technology™ (pgSIT) to disrupt pest reproduction and enhance crop yields without the use of pesticides or chemicals. The company addresses the challenges of crop damage and mosquito-borne diseases by providing environmentally friendly biological pest control solutions.

Amplifivascular offers the Amplifi Vein Dilation System, a wearable external blood pump that temporarily enlarges a patient’s vein before arteriovenous fistula (AVF) creation. By delivering controlled flow through dual catheters, the device rapidly dilates veins, increasing eligibility for AVF, shortening maturation time, and reducing early failure rates, and is removed prior to surgery.

Atomation develops wireless, battery-operated sensors that utilize edge computing to monitor equipment and machinery in real-time, providing immediate alerts for deviations from normal operational conditions. This technology enables proactive maintenance, reducing the risk of equipment failure and minimizing downtime across various industries.

Axioforce develops portable 3D force plates utilizing aerospace-derived smart materials for multidirectional force measurement. Their LaunchPad system provides real-time vertical, lateral, and rotational force data paired with integrated software. This technology offers lab-grade precision for performance analysis in training, laboratory, or field environments.

Bond Biosciences develops first-in-class non-absorbed oral therapeutics that bind excess dietary iron in the gastrointestinal tract to prevent iron overload in patients with Hereditary Hemochromatosis. Their lead product, BBI-001, offers a safe and effective alternative to phlebotomy, addressing the serious health risks associated with unmanaged iron levels, such as liver disease and diabetes.

Cadex Genomics develops molecular diagnostic tests that utilize next-generation sequencing to identify genetic mutations in tumors. These tests provide oncologists with precise information to tailor cancer treatment plans, improving patient outcomes and treatment efficacy.

Caeli Vascular develops catheter-based devices designed to improve outcomes for patients undergoing structural heart procedures. Their technology aims to enhance the safety and efficacy of transcatheter interventions.

Elira develops a drug-free wearable device that utilizes biofeedback technology to help users monitor and manage their weight. This device addresses the challenge of weight control by providing real-time insights into physiological responses, enabling users to make informed lifestyle choices.

Develops pharmacological agents that stimulate mitochondrial thermogenesis, activating calorie-burning processes previously inhibited by modern living conditions. This approach targets metabolic disorders, including obesity, by providing a drug-based solution for sustained weight loss and improved metabolic health.

Euphrates Vascular develops the Pulse NanoMED™ System, a nanoscale interventional device that utilizes magnetically enhanced iron-oxide nanoparticles to reach and disrupt distal vascular occlusions. This technology addresses the limitations of existing treatments for conditions like acute ischemic stroke and critical limb threatening ischemia, improving blood flow restoration and patient outcomes.

Forward utilizes sensors, mobile technology, and artificial intelligence to enhance healthcare delivery by providing real-time health monitoring and personalized care solutions. The platform addresses the inefficiencies in traditional healthcare systems, enabling timely interventions and improved patient outcomes.

Geneoscopy develops a noninvasive screening methodology for colorectal cancer by analyzing biomarkers present in stool samples. This approach enables early detection of the disease, improving patient outcomes and reducing the need for invasive diagnostic procedures.

The startup provides a technology platform that manages healthcare assets across multiple facilities and distributors, ensuring real-time availability of mental health, homelessness, and addiction services. This system enhances operational efficiency by streamlining resource allocation and improving access to critical support services for vulnerable populations.

Impetus Agriculture develops topical and transgenic insect control products that target agricultural pests, directly impacting crop yields. Their solutions enhance pest management efficiency while reducing the environmental footprint associated with conventional chemical pesticides.

InterShunt is developing a transcatheter system that excises tissue from the interatrial septum to create a left-to-right atrial shunt, effectively relieving elevated left atrial pressure in heart failure patients. This minimally invasive procedure aims to improve breathing and daily activity levels for over 6 million Americans suffering from heart failure.

Journeys Metabolic offers an interoperable digital therapeutic platform that utilizes machine learning and precision interventions to standardize in-home care for metabolic diseases. This platform addresses the challenges of high healthcare costs and poor patient outcomes by enabling health systems to implement value-based care models that improve long-term population health metrics.

KaloCyte is developing ErythroMer, a dried, bio-inspired artificial red blood cell designed to treat life-threatening blood loss when stored red blood cells are unavailable or undesirable. This technology aims to address the critical need for transfusion alternatives in pre-hospital settings and during mass casualty events.

Lalalog provides the Mash Fermentation System, an IoT‑enabled mushroom substrate production machine that uses a digital twin to continuously monitor and adjust temperature, humidity, CO₂ and moisture. The system automates environmental control, reduces labor, stabilizes yields, and offers a cloud dashboard for real‑time analytics and remote management, enabling small‑to‑medium growers and diversified farms to adopt low‑cost, data‑driven mushroom cultivation.

Lingrove manufactures ekoa®, a low-carbon natural fiber composite made from renewable plant-based fibers and resins, utilizing a proprietary process that ensures high durability and a superior strength-to-weight ratio. This material effectively replaces traditional wood, plastics, and metals in various applications, providing a sustainable solution for interior design and automotive finishes.

Provides a shared progress tracking platform for coaches and clients, enabling clients to log actions, track goals, and maintain accountability between sessions. Coaches gain measurable insights into client progress and engagement through customizable logs, reminders, and real-time feedback tools, improving the effectiveness of their practice.

Maxyfi offers automated debt collection and accounts receivable management software that utilizes centralized analytics and AI-based workflows to enhance recovery rates and operational efficiency. The platform addresses the challenges of manual debt recovery processes by minimizing human error and streamlining payment tracking through dedicated customer portals.

This company develops a fluorescent tracer system that, when paired with an optical skin sensor, continuously monitors organ function in real-time. This technology allows for improved patient outcomes and optimized dosing strategies in intensive care units and operating rooms.

Omniose is developing polysaccharide conjugate vaccines against serious bacterial infections using a proprietary bioconjugation platform that enables the simultaneous production of polysaccharide antigens and engineered carrier proteins within a single _E. coli_ cell. This technology addresses the limitations of traditional chemical conjugation methods, allowing for the precise attachment of a wide range of bacterial polysaccharide antigens to improve vaccine quality and efficacy.